4 ms·

GP probably meant for completely healthy people who are the target audience for doing these . Also the cancer drugs like PARP inhibitors seem to be helping eve

GP probably meant for completely healthy people who are the target audience for doing these . Also the cancer drugs like PARP inhibitors seem to be helping everyone regardless of mutation status in clinical trials. So the connection is much less clear.

pfdietz 4y ago
There are many cancer drugs that target mutations in specific proteins. Just what treatment will be given for a cancer often depends on what's been mutated.
- dominotw 4y ago
  > Just what treatment will be given for a cancer often depends on what's been mutated. What I was saying was that those drugs have been proving effective regardless of mutation status. So mutation x = give drug Y connection is not really well understood. Example, olaprib for Prostate cancer > the addition of olaparib was associated with a significantly prolonged radiographic PFS irrespective of HRR status https://www.practiceupdate.com/content/asco-gu-2022-propel-suggests-adding-olaparib-to-abiraterone-improves-outcomes-in-castration-resistant-prostate-cancer-regardless-of-homologous-recombination-repair-status/132359 https://www.practiceupdate.com/content/asco-gu-2022-propel-s...
  - pfdietz 4y ago
    > What I was saying was that those drugs have been proving effective regardless of mutation status. I don't believe this is the case in general. Indeed, all cancer drugs fail sometimes, and there has to be something different about the cancers they fail on. If not the mutation status, then what?
    - dominotw 4y ago
      I am not quite sure how to respond to 'I don't believe' response. Even FDA is approving these mutation targeting drugs without mutation status. Niraparib was approved for Ovarian Cancer even if you don't have HRD mutations. Approval was based on NOVA trial, you can lookup the details. I am not saying there isn't any connection, what I am saying is it not really well understood or clearcut as mutation x = drug y that general public believes about these drugs.

pfdietz 4y ago

There are many cancer drugs that target mutations in specific proteins. Just what treatment will be given for a cancer often depends on what's been mutated.

dominotw 4y ago
> Just what treatment will be given for a cancer often depends on what's been mutated. What I was saying was that those drugs have been proving effective regardless of mutation status. So mutation x = give drug Y connection is not really well understood. Example, olaprib for Prostate cancer > the addition of olaparib was associated with a significantly prolonged radiographic PFS irrespective of HRR status https://www.practiceupdate.com/content/asco-gu-2022-propel-suggests-adding-olaparib-to-abiraterone-improves-outcomes-in-castration-resistant-prostate-cancer-regardless-of-homologous-recombination-repair-status/132359 https://www.practiceupdate.com/content/asco-gu-2022-propel-s...
- pfdietz 4y ago
  > What I was saying was that those drugs have been proving effective regardless of mutation status. I don't believe this is the case in general. Indeed, all cancer drugs fail sometimes, and there has to be something different about the cancers they fail on. If not the mutation status, then what?
  - dominotw 4y ago
    I am not quite sure how to respond to 'I don't believe' response. Even FDA is approving these mutation targeting drugs without mutation status. Niraparib was approved for Ovarian Cancer even if you don't have HRD mutations. Approval was based on NOVA trial, you can lookup the details. I am not saying there isn't any connection, what I am saying is it not really well understood or clearcut as mutation x = drug y that general public believes about these drugs.